Clinical efficacy and safety of avastin combined with FOLFOX in the treatment of advanced metastatic colorectal cancer
10.13699/j.cnki.1001-6821.2015.22.010
- VernacularTitle:贝伐珠单抗联合FOLFOX治疗晚期转移性结直肠癌的临床疗效及安全性评价
- Author:
Yong-Zheng XIE
1
;
Xue-Qun REN
Author Information
1. 河南大学 淮河医院 普外科
- Keywords:
avastin;
chemotherapy;
metastasis colorectal cancer;
clinical efficacy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2015;31(22):2208-2210
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of avastin combined with FOLFOX in the treatment of advanced metastatic colorectal cancer.Methods Sixty-four patients with advanced meta-static colorectal cancer patients were divided into treatment group (31 cases) and control group (33 cases).Control group was treated with FOLFOX chemotherapy regimen, oxaliplatin 85 mg·m-2 +leucovorin 200 mg·m-2 +fluorouracil 400 mg·m-2 , once two week, 2 times for a course of treatment.Treatment group was based on the control group, and addition of bevacizumab 10 mg·kg -1 , in the second day after the start of intravenous chemotherapy, at least four times, two times a week to repeat.After two cycles of chemotherapy, the objective response rate and chemotherapy related adverse drug reactions were compared between the two groups.Results The objective response rates were 41.94%and 18.18% in treatment and control group with significant difference (P<0.05).The median survival of the treatment group were 12.6 months was much longer than that 9.1 months in control group ( P <0.05).But the grade Ⅲ-Ⅳchemotherapy related toxicity was not sta-tistical different between the two groups( P>0.05).Conclusion FOL-FOX combined with avastin can significantly improve the clinical efficacy in patients with metastasis colorectal cancer without increasing the risk of developing gradeⅢ-Ⅳadverse drug reactions.
